Siren, L.L.C. Bei Gene, Ltd. Transaction History
Siren, L.L.C.
- $2 Trillion
- Q3 2024
A detailed history of Siren, L.L.C. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Siren, L.L.C. holds 563,314 shares of BGNE stock, worth $107 Million. This represents 6.32% of its overall portfolio holdings.
Number of Shares
563,314Holding current value
$107 Million% of portfolio
6.32%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
250Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.01 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.23 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$986 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$948 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$706 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.8B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...